Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT04603183 2025-12-12

ABIGAIL

Phase 2 Completed

162 enrolled

Breast

Breast Cancer Metastatic

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Phase 2 Active not recruiting

60 enrolled

Breast

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

15 enrolled

Breast

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT07235618 2025-11-19

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2 Not yet recruiting

50 enrolled

Breast

Breast Neoplasms

NCT07180160 2025-11-18

ITHRAN

Phase 2 Recruiting

123 enrolled

Breast

Advanced Breast Cancer

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT03620643 2025-10-30

ROLo

Phase 2 Completed

33 enrolled 13 charts

BreastGastrointestinal

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

NCT05090358 2025-10-27

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2 Active not recruiting

15 enrolled

Breast

Breast Neoplasms

Clinical Trials

CAMERAN

Efficacy and Safety of 500mg of Fulvestrant

SEQUEL-Breast

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

LITESPARK-029

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

A Study of Lerociclib in Participants With Advanced Breast Cancer

optINAVO

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

PF-07104091 as a Single Agent and in Combination Therapy

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

FAIM

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

RaPhLRR

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

AMEERA-3

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

BYLieve

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

SUMIT-BC

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

ABIGAIL

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

ITHRAN

A Study of TAS-120 in Patients With Metastatic Breast Cancer

ROLo

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer